Ubiquigent
Ubiquigent is a UK-based life sciences tools provider, operating under the MRC Protein Phosphorylation Unit at the University of Dundee, that sells validated ubiquitin and phosphorylation research reagents and offers specialized profiling services (DUB, E3/E2 ligase, kinase, and KiPIK kinase identification) to academic and industrial researchers.
- Company typePrivate
- Founded2009
- HeadquartersDundee, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Ubiquigent does
Ubiquigent (operating commercially as "Ubiquigent Plus") is a UK-based life sciences research tools and services provider, incorporated in 2009 and headquartered at the University of Dundee in Scotland. The company operates as a commercial brand under the MRC Protein Phosphorylation Unit (MRC PPU), a UK government-funded research body, and benefits from institutional affiliation with the Medical Research Council and the University of Dundee. Its primary customers are academic and industrial life science researchers focused on the ubiquitin-proteasome system, protein phosphorylation, and kinase biology.
The company's product portfolio consists of two interconnected lines. First, it sells high-quality, validated research reagents for ubiquitin and phosphorylation research through an expanded catalogue distributed via its own website and the parent MRC PPU Reagents platform. Second, it offers specialized profiling and assay development services, including mass spectrometry-based deubiquitylating enzyme (DUB) profiling, E3 ligase and E2 profiling, kinase inhibitor screening, and the proprietary KiPIK method for kinase identification. These services are accessed via a network of dedicated sister sites (ubiquitylation.bio, dub-screen.mrc.ac.uk, kinase-screen.mrc.ac.uk, kipik.dundee.ac.uk) and email enquiry through the parent MRC PPU inbox.
Ubiquigent's revenue model combines one-time reagent sales with professional services revenue from bespoke profiling engagements. Distribution is direct-to-consumer via website and email, with no disclosed enterprise contracts or named customers. The company is privately held under a government research parent, has secured one disclosed equity round in 2013 ($804,727 from IP Group, Scottish Enterprise, and the Scottish Investment Bank) alongside non-dilutive grants from Innovate UK (2018) and UK Research and Innovation (2021), and operates with a small team of 1–10 employees under a leadership structure comprising CEO Jason Mundin, Founder & Managing Director Jason Brown, Chairman Mark Treherne, and Chief Scientific Officer Sheelagh Frame.
Ubiquigent firmographics
Firmographics- Name
- Ubiquigent
- Legal name
- MRC PPU (Medical Research Council Protein Phosphorylation Unit)
- Website
- https://ubiquigent.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Ubiquigent is a UK-based life sciences tools provider, operating under the MRC Protein Phosphorylation Unit at the University of Dundee, that sells validated ubiquitin and phosphorylation research reagents and offers specialized profiling services (DUB, E3/E2 ligase, kinase, and KiPIK kinase identification) to academic and industrial researchers.
- Ownership category
- akta.pro rank
Ubiquigent industry classification
Industry- Product category
- Drug Discovery Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)
- akta.pro secondary industries
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Proteomics & Mass Spectrometry Services (HLAGANAB), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)
Keywords
Where Ubiquigent is headquartered
LocationHeadquarters
- HQ city
- Dundee
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Ubiquigent business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Research Reagents Sales: Sale of high quality, validated reagents for ubiquitin and phosphorylation research through an expanded catalogue at lower prices
- DUB Profiling Services: Mass spectroscopy-based DUB profiling service for researchers studying deubiquitylating enzymes
- E3/E2 Ligase Profiling Services: Profiling services for E3 ligases and E2 enzymes involved in ubiquitin cascade research
- Kinase Profiling Services: Screening and profiling services for kinase inhibitors and kinase identification using KiPIK method
Go-to-market motion1 record
Distribution channels2 records
Marketing channels2 records
Ubiquigent product offering
Product offeringCore offering
Ubiquigent provides the research community with reagents, kits, and drug discovery, assay development and compound profiling services focused on the ubiquitin system and protein phosphorylation. Its offerings include validated ubiquitylation reagents, mass spectrometry-based DUB (deubiquitylating enzyme) profiling, E3/E2 ligase profiling, kinase inhibitor screening, and the proprietary KiPIK kinase identification method.
Product overview
Ubiquigent Plus is a unified platform for ubiquitin research reagents and services. The core offering includes Ubiquigent Plus itself, complemented by sister-site offerings: Ubiquitylation Reagents (curated reagent catalogue), DUB Profiling (mass spectrometry-based deubiquitylation analysis), E3 Ligase Profiling (E3/E2 enzyme profiling), Kinase Profiling (kinase inhibitor screening), and KiPIK (kinase identification method). All services are accessed through the parent organization MRC PPU Reagents and Services at Dundee University.
Differentiator
Problem solved
Functional benefit
Brands
- Ubiquitylation Reagents: Curated subset of reagents from MRC PPU Reagents and Services specifically selected for ubiquitin researchers.
- Deubiquitylation (DUB) Profiling
- E3 Ligase Profiling
- KiPIK
Products and services
- Ubiquigent Plus Reagents and Services Platform Primary platform providing high quality, validated reagents for ubiquitin research with an expanded catalogue and lower pricing, including many phosphorylation reagents. For academic and industrial life science researchers.
- Ubiquitylation Reagents A curated reagent catalogue from MRC PPU Reagents and Services specifically selected for ubiquitin researchers, covering protein ubiquitylation research tools.
- DUB Profiling Service Mass spectrometry-based deubiquitylation profiling service for analysing DUB enzyme activity, identifying and characterising deubiquitylating enzymes. For academic and industrial life science researchers.
- E3 Ligase Profiling Service Service for profiling E3 ligases with E2 profiling also available as part of the ubiquitin cascade research toolkit. Enquiries managed via MRC PPU Reagents.
- Kinase Profiling Service Kinase screening service for finding and testing kinase inhibitors, supporting protein phosphorylation research linked to ubiquitin studies.
- KiPIK Kinase Identification A novel method for kinase identification developed by the MRC PPU at the University of Dundee, offered as a standalone profiling/identification service.
Quantifiable outcome
- Reagents available at lower prices compared to previous offering
Companies that use Ubiquigent
Customer profileSegments2 records
Ideal customer profiles2 records
Ubiquigent technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Ubiquigent partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- MRC PPU (Medical Research Council Protein Phosphorylation Unit)coreMRC PPU is the parent organization of Ubiquigent, providing institutional affiliation with the Medical Research Council and access to research expertise. Ubiquigent operates as part of MRC PPU Reagents and Services.
- Dundee University (University of Dundee)coreUbiquigent is located at Dundee University and benefits from the academic research environment. The partnership provides access to world-class research facilities and expertise in protein phosphorylation and ubiquitination.
Scale indicators1 record
Recent moves6 records
Expansion highlights4 records
Ubiquigent competitors and assessment
Company assessmentBroad incumbents
- Merck (Sigma-Aldrich): Sigma-Aldrich/Merck sells an enormous life sciences research reagent catalogue, including kinase and ubiquitin-related tools, and competes broadly with Ubiquigent Plus on validated reagent quality and breadth.
- Thermo Fisher Scientific: Thermo Fisher is the dominant life sciences tools company selling reagents, kits, and mass spectrometry-based proteomics services across most research areas, including the ubiquitin and kinase space Ubiquigent serves.
- Promega: Promega supplies a broad range of life science research reagents, assay kits, and drug discovery tools (including for protein degradation research), overlapping Ubiquigent's reagent and services offering at much larger scale.
- Cell Signaling Technology (CST): CST is a major research antibody and reagent company with strong coverage of ubiquitination, phosphorylation, and cell signaling pathways, competing with Ubiquigent in the validated-reagent segment.
- Bio-Techne (Tocris): Bio-Techne's Tocris brand is a leading supplier of life science research reagents, including kinase inhibitors and tools for cell signaling research, directly competitive with Ubiquigent Plus reagent catalogue but at much broader scale.
Direct peers
- LifeSensors: LifeSensors is the most direct competitor - it specializes in ubiquitin and ubiquitin-like (UBL) pathway research reagents, profiling services, and tools for protein degradation studies, directly overlapping Ubiquigent's niche.
- BPS Bioscience: BPS Bioscience provides recombinant enzymes, assay kits, and drug discovery services across ubiquitin-related targets (E3 ligases, DUBs) and kinases, overlapping with both Ubiquigent's reagent and profiling service businesses.
- Reaction Biology: Reaction Biology offers kinase profiling services (including the famous HotSpot kinase assay) and broader enzyme/cro services, directly comparable to Ubiquigent's Kinase Profiling offering.
- Eurofins Discovery (DiscoverX): Eurofins Discovery / DiscoverX offers kinase, protease, and other enzyme profiling services along with cell-based assays, directly comparable to Ubiquigent's profiling services portfolio.
Emerging players
- Cayman Chemical: Cayman Chemical supplies biochemical research tools, assay kits, and inhibitor libraries including kinase and ubiquitin-related products, offering a comparable though broader-purposed catalogue to academic and pharma researchers.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Ubiquigent social profiles
Digital presenceUbiquigent financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ubiquigent leadership team
Management profileNumber of profiles
Profiles4 records
Ubiquigent funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ubiquigent M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ubiquigent
What does Ubiquigent do?
Ubiquigent provides the research community with reagents, kits, and drug discovery, assay development and compound profiling services focused on the ubiquitin system and protein phosphorylation. Its offerings include validated ubiquitylation reagents, mass spectrometry-based DUB (deubiquitylating enzyme) profiling, E3/E2 ligase profiling, kinase inhibitor screening, and the proprietary KiPIK kinase identification method.
Is Ubiquigent a public or private company?
Ubiquigent is a private company. It is classified as state government owned and is currently operating.
When was Ubiquigent founded?
Ubiquigent was founded in 2009. It employs 1 to 10 people.
Where is Ubiquigent based?
Ubiquigent is headquartered in Dundee, United Kingdom, in the Europe region.
How does Ubiquigent make money?
Four revenue lines are on record. Research Reagents Sales are the primary driver. The others are DUB Profiling Services, E3/E2 Ligase Profiling Services and kinase Profiling Services.
Who are Ubiquigent's main competitors?
Broad incumbents on record are Merck (Sigma-Aldrich), Thermo Fisher Scientific, Promega, Cell Signaling Technology (CST) and Bio-Techne (Tocris). Direct peers are LifeSensors, BPS Bioscience, Reaction Biology and Eurofins Discovery (DiscoverX). Cayman Chemical is listed as an emerging player.
Does Ubiquigent have an API?
No public API is recorded for Ubiquigent.
What industry is Ubiquigent in?
Ubiquigent's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes), with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.